Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247
Inflammatory Response01:28

Inflammatory Response

4.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
4.8K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

413
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
413
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

552
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
552
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

520
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
520
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

602
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
602

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sustainable synergistic strategy for photocatalytic and <i>Bacillus velezensis</i>-mediated biodegradation of TiO₂-incorporated LDPE with agricultural valorization.

Environmental technology·2026
Same author

Surgical and Functional outcome of Infective Knee Operated with Arthrotomy.

Journal of orthopaedic case reports·2026
Same author

Ovarian hormones and obesity drive Th17-mediated airway inflammation through estrogen receptor-α signaling.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Evaluation of microleakage in composite restorations with various adhesive systems: An <i>in vitro</i> comparison.

Bioinformation·2026
Same author

A Case of Atypical Acute Encephalopathy Unmasking IgA Multiple Myeloma.

Cureus·2026
Same author

Genetic diversity of Collaborative Cross mice implicates FFAR3 as a target for ILC2 anti-inflammatory reprogramming.

Nature communications·2026

Related Experiment Video

Updated: Aug 22, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.6K

Prostacyclin Regulation of Allergic Inflammation.

Kunj Patel1,2, R Stokes Peebles1,3,4

  • 1Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2650, USA.

Biomedicines
|November 11, 2022
PubMed
Summary

Prostacyclin, a compound from the cyclooxygenase pathway, shows strong anti-inflammatory effects in allergic airway inflammation models. It inhibits key immune cells, suggesting its potential as a novel therapeutic target for asthma and allergic conditions.

Keywords:
airway remodelingallergic inflammationanti-inflammatorycytokinesproinflammatoryprostacyclin

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.6K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.6K

Related Experiment Videos

Last Updated: Aug 22, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.6K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.6K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

3.6K

Area of Science:

  • Immunology
  • Pharmacology
  • Respiratory Medicine

Background:

  • Prostacyclin is a cyclooxygenase pathway metabolite with known vasodilatory properties.
  • Historically used for pulmonary hypertension, its anti-inflammatory roles are increasingly recognized.
  • Inflammatory conditions can induce prostacyclin expression.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of prostacyclin in allergic airway inflammation.
  • To elucidate the cellular mechanisms underlying prostacyclin's anti-inflammatory actions.
  • To evaluate prostacyclin as a potential therapeutic target for allergic diseases.

Main Methods:

  • Utilized animal models of allergic airway inflammation.
  • Conducted in vitro studies on immune cells, including CD4+ Th2 cells, ILC2, and dendritic cells.
  • Assessed prostacyclin's impact on cytokine production and T cell activation.

Main Results:

  • Prostacyclin demonstrated potent anti-inflammatory effects in allergic airway inflammation models.
  • In vitro, prostacyclin directly inhibited type 2 cytokine production from CD4+ Th2 cells and ILC2.
  • Prostacyclin reduced dendritic cell-mediated Th2 cytokine generation in an antigen-specific manner.

Conclusions:

  • Prostacyclin exhibits significant anti-inflammatory properties relevant to allergic airway diseases.
  • The direct inhibition of key immune cells and cytokine production supports its therapeutic potential.
  • Prostacyclin represents a promising therapeutic target for human allergic inflammation and asthma.